Sana Biotechnology’s Engineered Pancreatic Islet Cells Control Blood Sugar in Monkey Model of Type 1 Diabetes


Sana Biotechnology, based in Seattle, published preclinical data demonstrating the company successfully controlled glucose levels in a diabetic primate through genetically engineered pancreatic islet cells.

The results were published in a Cell Stem Cell paper titled, “Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate.”

In the company’s press release, Sonja Schrepfer, MD, PhD, Sana’s Head of Hypoimmune Platform said, “The results of this preclinical study are remarkable, and if they translate into the clinic, we have the potential to profoundly change the way that Type 1 diabetes is addressed, potentially eliminating the need for insulin injections or immunosuppression.”